TargetCancer, Inc. was founded by Paul Poth in April 2009 to respond to a very specific need with a very specific strategy.
The need is for funding and directed research into rare and lesser known cancers, which lack specific treatment protocols. In most cases, treatment for these cancers is extrapolated from regimens for other cancers, and patched together in an educated guess approach. Since these cancers are so rare, there is little if any support for their research.
The strategy is to raise enough money to fund defined, cutting edge research that can quickly benefit those suffering from cancers with no protocols for treatment. Ultimately, advances in treating lesser known cancers would likely be of benefit to all types of cancers. TargetCancer supports new therapies that scientists believe are the future of cancer treatment, including molecularly targeted cancer therapies and tumor genotyping. It is clear that traditional therapies are not the only answer, especially for cancers that are more advanced or difficult to treat. It is time to find a method that treats the individual based on their genetic make up, instead of relying solely on treatments which themselves can be physically devastating.
TargetCancer promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.